A phase 1, randomized, double-blind, placebo-controlled dosage escalation trial to evaluate the safety and immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted in HIV-uninfected, healthy adult volunteers

This is a phase 1 first-in-human clinical trial to assess the safety, tolerability, and immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted, in up to 48 healthy adult HIV-negative volunteers.

Sponsor(s)
International AIDS Vaccine Initiative
Principal Investigator(s)
David Diemert, MD/Medicine
Contact Phone Number